This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation) (DECIDE)

This study has been terminated.
Information provided by:
Conor Medsystems Identifier:
First received: February 23, 2007
Last updated: October 29, 2009
Last verified: October 2009
The primary objective of this study is to evaluate the safety and effectiveness of a direct stenting technique compared to conventional stenting with pre-dilatation strategy using the CoStar Paclitaxel-eluting coronary stent system for the treatment of a single de novo lesion in a native coronary artery ≤ 25 mm long in a native coronary artery 2.5-3.5 mm diameter.

Condition Intervention Phase
Coronary Artery Disease Device: CoStar Paclitaxel-eluting coronary stent system Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The DECIDE Trial: Prospective, Multi-center, Randomized Study to Evaluate the CoStar Paclitaxel-Eluting Coronary Stent System Using a Direct Stenting Technique Compared to Conventional Stenting With Pre-dilatation Strategy

Resource links provided by NLM:

Further study details as provided by Conor Medsystems:

Primary Outcome Measures:
  • Adjudicated MACE at 30 days [ Time Frame: 30 days ]

Secondary Outcome Measures:
  • Primary & second. device success, Lesion and Procedure success, Adjudicated MACE 8, 9, 12, 24 mos post-proc; Binary restenosis, MLD, Clin. driven TLR 8 mos post-proc; Clinic. driven TVR 8 mos post-proc; Overall TVR/TLR 8 mos post-proc; Stent thrombosis [ Time Frame: 8, 9, 12, 24 mos post-proc ]

Enrollment: 18
Study Start Date: February 2007
Study Completion Date: July 2009
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Direct stenting technique
Device: CoStar Paclitaxel-eluting coronary stent system
Experimental: 2
Conventional stenting with pre-dilatation strategy
Device: CoStar Paclitaxel-eluting coronary stent system

Detailed Description:
Prospective, multi-center, randomized (1:1), open-label study to evaluate direct stenting compared to conventional stenting with pre-dilatation strategy in treatment of a single de novo Lesion of a single native coronary artery in patients undergoing elective percutaneous coronary intervention.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eligible for percutaneous coronary intervention
  • Documented stable or unstable angina pectoris or with documented ischemia, or with documented silent ischemia
  • Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks
  • Acceptable candidate for coronary artery bypass graft surgery
  • Single target vessel / single target lesion to be treated
  • Target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent
  • Cumulative target lesion length per vessel is ≤ 25 mm
  • RVD of 2.5-3.5 mm
  • Target lesion diameter stenosis ≥ 50% and < 100%
  • Target vessel has not undergone prior revascularization within the preceding 6 months

Exclusion Criteria:

  • Known sensitivity to cobalt chromium, Paclitaxel or PLGA
  • Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q-wave, or a creatine kinase (CK) level of > 2x the laboratory upper limits of normal and elevated MB
  • The patient is in cardiogenic shock
  • Cerebrovascular Accident (CVA) within the past 6 months
  • Acute or chronic renal dysfunction (creatinine > 2.0 mg/dL or > 150 µmol/L)/
  • Contraindication to ASA or to Clopidogrel
  • Thrombocytopenia (platelet count <100,000/mm3)
  • Active gastrointestinal (GI) bleeding within the past three months
  • Any prior true anaphylactic reaction to contrast agents
  • Patient is currently taking Colchicine
  • Patient is currently, or has been treated with Paclitaxel (systemic) within12 months of the index procedure
  • Comorbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
  • Left main coronary artery disease (stenosis >50%), whether protected or unprotected.
  • Target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter that requires intervention.
  • Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1).
  • The target vessel has had prior drug-eluting stent placement to vessel segment (or branch) proximal to intended target lesion site.
  • Angiographic restenosis of any segment of the target vessel that has undergone prior PCI.
  • Angiographic evidence of atherosclerotic disease with >50% diameter stenosis (by visual estimate) proximal or distal to the target lesion (applies to the major epicardial portion of the target vessel and contiguous vessel segment if the target lesion is located in a branch vessel)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00440674

Universitäres Herz-und Gefäßzentrum Hamburg
Hamburg, Germany, D-22527
Sponsors and Collaborators
Conor Medsystems
Principal Investigator: Joachim Schofer Universitäres Herz-und Gefäßzentrum Hamburg
  More Information

Responsible Party: Joachim Schofer, Principal Investigator, Universitäres Herz-und Gefäßzentrum Hamburg Identifier: NCT00440674     History of Changes
Other Study ID Numbers: The DECIDE Trial: CP-05
Study First Received: February 23, 2007
Last Updated: October 29, 2009

Keywords provided by Conor Medsystems:
Direct Stenting
Drug-eluting stent

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Dilatation, Pathologic
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Pathological Conditions, Anatomical
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017